Taiwan's RSV vaccine heads toward the clinic

Respiratory syncytial virus (RSV) infection is common in Taiwan. It peaks in the spring and fall, and often seems to be caught during hospital stays (nosocomial infections). While most people quickly shrug it off, in children or elderly people who are already vulnerable due to illness or injury, RSV infection can be serious. To combat this, Taiwanese researchers are developing a virus-based vaccine that could complete preclinical studies next year, and has already shown signs of efficacy. The vaccine, developed by the Taiwanese National Institute of Infectious Diseases and Vaccinology and Taipei-based TWi Biotechnology, is based on adenovirus technology. It will be manufactured according to FDA current Good Manufacturing Practice (cGMP) guidelines, and the researchers plan to carry out clinical trials in the U.S. Article

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.